«DATATOP subjects were recruited at early disease stages, without
apparent signs of dementia and prior to needing dopamine - supplementing drugs, making this cohort ideal for studying PD progression,» explains Jing Zhang, MD, PhD, Department of Pathology at the University of Washington School of Medicine (Seattle).